148 related articles for article (PubMed ID: 17416771)
1. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
Tworoger SS; Lee IM; Buring JE; Rosner B; Hollis BW; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):783-8. PubMed ID: 17416771
[TBL] [Abstract][Full Text] [Related]
2. Plasma androgen concentrations and risk of incident ovarian cancer.
Tworoger SS; Lee IM; Buring JE; Hankinson SE
Am J Epidemiol; 2008 Jan; 167(2):211-8. PubMed ID: 17982156
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
Tworoger SS; Lee IM; Buring JE; Pollak MN; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1691-5. PubMed ID: 17684148
[TBL] [Abstract][Full Text] [Related]
4. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer.
Bertone-Johnson ER; Chen WY; Holick MF; Hollis BW; Colditz GA; Willett WC; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1991-7. PubMed ID: 16103450
[TBL] [Abstract][Full Text] [Related]
5. Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women Followed over 20 Years.
Eliassen AH; Warner ET; Rosner B; Collins LC; Beck AH; Quintana LM; Tamimi RM; Hankinson SE
Cancer Res; 2016 Sep; 76(18):5423-30. PubMed ID: 27530324
[TBL] [Abstract][Full Text] [Related]
6. Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study.
Toriola AT; Surcel HM; Calypse A; Grankvist K; Luostarinen T; Lukanova A; Pukkala E; Lehtinen M
Eur J Cancer; 2010 Oct; 46(15):2799-805. PubMed ID: 20601305
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies.
Tworoger SS; Gates MA; Lee IM; Buring JE; Titus-Ernstoff L; Cramer D; Hankinson SE
Cancer Res; 2009 Mar; 69(5):1885-91. PubMed ID: 19223536
[TBL] [Abstract][Full Text] [Related]
8. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer.
Wu K; Feskanich D; Fuchs CS; Willett WC; Hollis BW; Giovannucci EL
J Natl Cancer Inst; 2007 Jul; 99(14):1120-9. PubMed ID: 17623801
[TBL] [Abstract][Full Text] [Related]
9. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
Zheng W; Danforth KN; Tworoger SS; Goodman MT; Arslan AA; Patel AV; McCullough ML; Weinstein SJ; Kolonel LN; Purdue MP; Shu XO; Snyder K; Steplowski E; Visvanathan K; Yu K; Zeleniuch-Jacquotte A; Gao YT; Hankinson SE; Harvey C; Hayes RB; Henderson BE; Horst RL; Helzlsouer KJ
Am J Epidemiol; 2010 Jul; 172(1):70-80. PubMed ID: 20562186
[TBL] [Abstract][Full Text] [Related]
10. Casting light on 25-hydroxyvitamin D deficiency in ovarian cancer: a study from the NHANES.
Bakhru A; Mallinger JB; Buckanovich RJ; Griggs JJ
Gynecol Oncol; 2010 Nov; 119(2):314-8. PubMed ID: 20684976
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Freedman DM; Chang SC; Falk RT; Purdue MP; Huang WY; McCarty CA; Hollis BW; Graubard BI; Berg CD; Ziegler RG
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):889-94. PubMed ID: 18381472
[TBL] [Abstract][Full Text] [Related]
12. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II.
Eliassen AH; Spiegelman D; Hollis BW; Horst RL; Willett WC; Hankinson SE
Breast Cancer Res; 2011 May; 13(3):R50. PubMed ID: 21569367
[TBL] [Abstract][Full Text] [Related]
13. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
Platz EA; Leitzmann MF; Hollis BW; Willett WC; Giovannucci E
Cancer Causes Control; 2004 Apr; 15(3):255-65. PubMed ID: 15090720
[TBL] [Abstract][Full Text] [Related]
14. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer.
Wolpin BM; Ng K; Bao Y; Kraft P; Stampfer MJ; Michaud DS; Ma J; Buring JE; Sesso HD; Lee IM; Rifai N; Cochrane BB; Wactawski-Wende J; Chlebowski RT; Willett WC; Manson JE; Giovannucci EL; Fuchs CS
Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):82-91. PubMed ID: 22086883
[TBL] [Abstract][Full Text] [Related]
15. Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.
Rice MS; Rist PM; Winter AC; Kurth T; Tworoger SS
Int J Cancer; 2018 Feb; 142(3):534-539. PubMed ID: 28929486
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.
Ma J; Stampfer MJ; Gann PH; Hough HL; Giovannucci E; Kelsey KT; Hennekens CH; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 1998 May; 7(5):385-90. PubMed ID: 9610787
[TBL] [Abstract][Full Text] [Related]
17. Surrogates of long-term vitamin d exposure and ovarian cancer risk in two prospective cohort studies.
Prescott J; Bertrand KA; Poole EM; Rosner BA; Tworoger SS
Cancers (Basel); 2013 Nov; 5(4):1577-600. PubMed ID: 24351671
[TBL] [Abstract][Full Text] [Related]
18. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum.
Platz EA; Hankinson SE; Hollis BW; Colditz GA; Hunter DJ; Speizer FE; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1059-65. PubMed ID: 11045788
[TBL] [Abstract][Full Text] [Related]
19. Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies.
Peres LC; Townsend MK; Birmann BM; Conejo-Garcia JR; Kim Y; Kubzansky LD; Magpantay LI; Martinez-Maza O; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):710-718. PubMed ID: 33563649
[TBL] [Abstract][Full Text] [Related]
20. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality.
Dobnig H; Pilz S; Scharnagl H; Renner W; Seelhorst U; Wellnitz B; Kinkeldei J; Boehm BO; Weihrauch G; Maerz W
Arch Intern Med; 2008 Jun; 168(12):1340-9. PubMed ID: 18574092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
